Current calls, week 49, 2022
Tips from KI Grants Office about current calls.
Swedish and Nordic calls
The Foundation Blanceflor - Application Window for 2023 Scholarships
Entitled to apply are Italian and Swedish citizens having a study or research project on higher academic level to be carried out abroad, in certain countries. The Scholarship is aimed to support personal expenses in connection, not institutional costs.
All the relevant information is to be found at our website together with the Application Form.
Closing date: February 1, 2023
Letterstedtska föreningen utlyser anslag till ansökan under 2023
Letterstedtska föreningens uppgift är att befordra gemenskapen mellan de fem nordiska länderna på industrins, vetenskapens och konstens områden. Föreningen delar ut anslag till nordiska ändamål, dels gemensamt, dels nationellt. Under 2023 kommer anslag att utdelas vid två tillfällen, dels under våren, dels under hösten. . Ansökan görs företrädesvis på skandinaviska språk. Alla mottagna ansökningar bekräftas. Besked om utdelade anslag ges i juni resp. november 2023.
Det belopp som står till förfogande 2023 för gemensam utdelning uppgår till 1.000.000:- SEK. Ansökningsbeloppet bör ligga i intervallet 10.000 till 50.000 SEK.
Closing date: Ansökan skall insändas senast den 15 februari och senast den 15 september
Visiting professorships - Danish Diabetes Academy (DDA)
Support collaborations between Danish and international research groups in the field of diabetes research. Applications supporting the three major strategic areas of the DDA, namely internationalisation, interdisciplinarity and collaboration across sectors, will be prioritised. Applicants may be senior academics, such as senior lecturers, associate professors or above, who hold a PhD. Applicants must be employed at a university outside of Denmark, and intend to collaborate with one or more researchers at a Danish research institution. In addition, they must have an excellent academic record and must be able to document teaching experience.
Grants are worth up to DKK 250,000, covering expenses for visiting Denmark for a period of up to six months, including salary, travel and accommodation. Up to four grants are available.
Closing date: February 7, 2023
Travel grants for doctoral students in preclinical and clinical medical research - Swedish Society for Medical Research (SSMF)
Aim to cover personal costs in connection with travel to another research institution or clinic for studies of significance to the applicant's own research project. Grants are worth up to SEK 50,000 and are granted a maximum of three times.
Closing date: March 1, 2023
Travel grants - Radiumhemmets Forskningsfonder
Support research associated participation in courses and congresses within clinical cancer research. Grants normally cover return tickets partly or in full to the lowest ticket cost, hotel costs, registration fee and transfer to and from the airport.
Closing date: March 1, 2023
Stipendier - Riksföreningen för Sjuksköterskor inom Urologi
Stöder sjuksköterskor till utveckling av vården av urologiska patienter. Stipendier kan sökas för resor för konferenser, utvecklings- och förbättringsarbeten, kurser, utbildningar och hospiteringar. Behöriga att söka är legitimerade sjuksköterskor som arbetar inom urologi och har varit medlemmar i föreningen i minst ett år. Den totala budgeten är SEK 30,000 per år.
Closing date: April 30, 2023
European calls
José Baselga fellowship for clinician scientists. European Society for Medical Oncology, EUR
The European Society for Medical Oncology, sponsored by AstraZeneca, invites applications for the José Baselga fellowship for clinician scientists. This supports physicians in the field of oncology who are developing their careers as clinician-scientists by providing protected time for research. The fellow will be paired with a mentor who is a member of the ESMO faculty corresponding to their field of research.
Eligibility criteria:
- Applicants must be qualified medical or clinical oncologists with at least one year of experience in medical, radiation or surgical oncology and be currently engaged in cancer research or clinical oncology practice.
- They must be an ESMO member
- Must be under the age of 40 when applying.
The fellowship must take place at a European institution and fellows are expected to spend at least 50 per cent of their time on a research project.
Budget: Funding is worth €200,000 to supplement the salary of one fellow over a period of three years. The fellow will also receive free registration to the ESMO annual congress and to any other meetings which are relevant to the area of their research.
Closing date: 16th January 2023
Research Grants. RP Fighting Blindness, GB
Retina UK invites applications for its research grants. These support research projects looking at the causes and potential treatments for all forms of inherited retinal disease. Retina UK has been offered a generous donation to fully fund one research project to accelerate progress towards a therapy to address sight loss in USH2A-mediated retinitis pigmentosa. Retina UK therefore invites applications for a grant to address mutation-independent therapy development specifically for USH2A-associated retinitis pigmentosa, or therapy development for retinitis pigmentosa that would also benefit USH2A patients. Proposals should be aimed at improving vision, or preventing or slowing further vision loss, and should have significant translational potential.
Eligibility criteria:
The charity mainly funds research in the UK. Applications from other countries may be considered, but are only likely to be funded if they demonstrate exceptional quality and meaningful collaboration with UK scientists and institutions.
Budget:
Funding is granted for one year, with the possibility of subsequent extensions. This grant round will result in one award only, with a maximum budget of £250,000, which will be fully covered by the donation and will not impact on other Retina UK research funds.
Closing date: 1 Feb 2023.
Research unit. European Society for Paediatric Endocrinology, EUR
The European Society for Paediatric Endocrinology, with support from Sandoz, invites applications for its research unit. This supports collaborative research in paediatric endocrinology.
Eligibility criteria:
Members of ESPE may apply. Each application must include at least one principal investigator and two co-investigators who are ESPE members. Non-ESPE members may participate as additional co-investigators. Applications that consist of investigators from at least three different countries are encouraged. The majority of the research should be performed at the investigators’ centre.
Budget:
One large grant is available annually. The large grant is worth €100,000 for a period of two years. The large grant covers salary, materials and consumables, small items of equipment, collaborative visits and overheads.
Closing date: 15th February 2023 (preliminary application), 20th April 2023 (Full application upon invitation)
US calls
Federal Funding agencies
Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. Generation of new primary data is not allowed.
Deadline: February 28, 2023, October 28, 2023, February 28, 2024, October 28, 2024, February 28, 2025, October 28, 2025. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-23-036
NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required): NIH
This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.
Deadline: March 07, 2023 and NIH standard due dates until January 08, 2026. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-23-057
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Deadline: March 01, 2023 & September 01, 2023. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-CA-23-002
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Deadline: March 01, 2023 & September 01, 2023. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-CA-23-003
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Deadline: March 01, 2023 & September 01, 2023. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-CA-23-004
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Deadline: March 01, 2023 & September 01, 2023. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-CA-23-005
Foundations
Clinic and Laboratory Integration Program (CLIP), Cancer Research Institute (CRI), US
CLIP supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CLIP grants are awarded to qualified scientists exploring clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. This CLIP aimed at improving outcomes for two rare cancers: gastroesophageal cancer and chordoma. CLIP grants provide $200,000 over two years.
Deadline: January 15, 2023 (LOI) extended; March 1, 2023 (Full proposal).
Lysosomal Biomarkers Program, The Michael J. Fox Foundation (MJFF), US
This program seeks to develop, optimize and validate biomarkers related to lysosomal function, protein clearance and lipid homeostasis. MJFF will consider applications spanning all stages of the biomarker pipeline, including development, optimization and validation. Applicants are encouraged to get creative and think outside the box when considering how to address challenges surrounding measurements of this pathway.
For this round, MJFF will prioritize proposals that:
- Have potential to directly inform ongoing or upcoming clinical trials,
- Directly inform precision medicine approaches for patient selection & stratification,
- Include clear indication of how the proposed biomarker will be used to inform PD diagnosis, prognosis, monitoring, prediction, susceptibility, and/or pharmacodynamic response
Clear translational value and path to the use of the assay in the clinic should be described if fibroblasts or iPSCs are used. The duration of this grant is between 12 to 24 months and award amount is up to 350,000 USD.
Deadline: January 17, 2023 (Pre-proposal); May 11, 2023 (Full proposal by invitation only).